Literature DB >> 20104214

Rational design of micro-RNA-like bifunctional siRNAs targeting HIV and the HIV coreceptor CCR5.

Ali Ehsani1, Pål Saetrom, Jane Zhang, Jessica Alluin, Haitang Li, Ola Snøve, Lars Aagaard, John J Rossi.   

Abstract

Small-interfering RNAs (siRNAs) and micro-RNAs (miRNAs) are distinguished by their modes of action. SiRNAs serve as guides for sequence-specific cleavage of complementary mRNAs and the targets can be in coding or noncoding regions of the target transcripts. MiRNAs inhibit translation via partially complementary base-pairing to 3' untranslated regions (UTRs) and are generally ineffective when targeting coding regions of a transcript. In this study, we deliberately designed siRNAs that simultaneously direct cleavage and translational suppression of HIV RNAs, or cleavage of the mRNA encoding the HIV coreceptor CCR5 and suppression of translation of HIV. These bifunctional siRNAs trigger inhibition of HIV infection and replication in cell culture. The design principles have wide applications throughout the genome, as about 90% of genes harbor sites that make the design of bifunctional siRNAs possible.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20104214      PMCID: PMC2862539          DOI: 10.1038/mt.2009.321

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  30 in total

1.  Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation.

Authors:  Eric C Lai
Journal:  Nat Genet       Date:  2002-03-18       Impact factor: 38.330

2.  Expression profiling reveals off-target gene regulation by RNAi.

Authors:  Aimee L Jackson; Steven R Bartz; Janell Schelter; Sumire V Kobayashi; Julja Burchard; Mao Mao; Bin Li; Guy Cavet; Peter S Linsley
Journal:  Nat Biotechnol       Date:  2003-05-18       Impact factor: 54.908

Review 3.  MicroRNAs: genomics, biogenesis, mechanism, and function.

Authors:  David P Bartel
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

4.  MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms.

Authors:  Yan Zeng; Rui Yi; Bryan R Cullen
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-05       Impact factor: 11.205

5.  Specificity of microRNA target selection in translational repression.

Authors:  John G Doench; Phillip A Sharp
Journal:  Genes Dev       Date:  2004-03-10       Impact factor: 11.361

6.  Human immunodeficiency virus type 1 escape from RNA interference.

Authors:  Daniel Boden; Oliver Pusch; Frederick Lee; Lynne Tucker; Bharat Ramratnam
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

7.  Prediction of mammalian microRNA targets.

Authors:  Benjamin P Lewis; I-hung Shih; Matthew W Jones-Rhoades; David P Bartel; Christopher B Burge
Journal:  Cell       Date:  2003-12-26       Impact factor: 41.582

8.  Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells.

Authors:  Sandeep Saxena; Zophonías O Jónsson; Anindya Dutta
Journal:  J Biol Chem       Date:  2003-09-02       Impact factor: 5.157

9.  Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages.

Authors:  Erwei Song; Sang-Kyung Lee; Derek M Dykxhoorn; Carl Novina; Dong Zhang; Keith Crawford; Jan Cerny; Phillip A Sharp; Judy Lieberman; N Manjunath; Premlata Shankar
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

10.  Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron.

Authors:  Ying Poi Liu; Joost Haasnoot; Olivier ter Brake; Ben Berkhout; Pavlina Konstantinova
Journal:  Nucleic Acids Res       Date:  2008-03-16       Impact factor: 16.971

View more
  8 in total

Review 1.  RNAi and small interfering RNAs in human disease therapeutic applications.

Authors:  Monica R Lares; John J Rossi; Dominique L Ouellet
Journal:  Trends Biotechnol       Date:  2010-09-15       Impact factor: 19.536

2.  Current progress and challenges in HIV gene therapy.

Authors:  Janet Chung; John J Rossi; Ulrike Jung
Journal:  Future Virol       Date:  2011-11-01       Impact factor: 1.831

Review 3.  Current translational and clinical practices in hematopoietic cell and gene therapy.

Authors:  David L Digiusto; Hans-Peter Kiem
Journal:  Cytotherapy       Date:  2012-08       Impact factor: 5.414

4.  Ago-2-mediated slicer activity is essential for anti-flaviviral efficacy of RNAi.

Authors:  Shuiping Chen; Harendra S Chahar; Sojan Abraham; Haoquan Wu; Theodore C Pierson; Xiaozhong A Wang; N Manjunath
Journal:  PLoS One       Date:  2011-11-10       Impact factor: 3.240

5.  IL-27 receptor signaling regulates CD4+ T cell chemotactic responses during infection.

Authors:  Emily Gwyer Findlay; Ana Villegas-Mendez; J Brian de Souza; Colette A Inkson; Tovah N Shaw; Christiaan J Saris; Christopher A Hunter; Eleanor M Riley; Kevin N Couper
Journal:  J Immunol       Date:  2013-03-27       Impact factor: 5.422

6.  Transfer and Expression of Small Interfering RNAs in Mammalian Cells Using Lentiviral Vectors.

Authors:  T D Lebedev; P V Spirin; V S Prassolov
Journal:  Acta Naturae       Date:  2013-04       Impact factor: 1.845

7.  Embedding siRNA sequences targeting apolipoprotein B100 in shRNA and miRNA scaffolds results in differential processing and in vivo efficacy.

Authors:  Piotr Maczuga; Jacek Lubelski; Richard van Logtenstein; Florie Borel; Bas Blits; Erwin Fakkert; Adalberto Costessi; Derek Butler; Sander van Deventer; Harald Petry; Annemart Koornneef; Pavlina Konstantinova
Journal:  Mol Ther       Date:  2012-10-23       Impact factor: 11.454

Review 8.  C-C chemokine receptor type five (CCR5): An emerging target for the control of HIV infection.

Authors:  Fatima Barmania; Michael S Pepper
Journal:  Appl Transl Genom       Date:  2013-05-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.